Clinical trials: Endocrine Disorder
Primary Aldosteronism
Primary Aldosteronism LC-MS/MS-specific Cutoffs
Aims to evaluation the LC-MS/MS-specific cutoffs of PA screening and CCT test.
- Trial name
- PM (NCT05959863)
- Testing
- Captopril Challenge Test
- Where
- 2 sites in China
- Volunteers
- 396 people
- Sponsor
- Chongqing Medical University
Papillary Thyroid Cancer
Image-guided Thermal Ablation vs. Lobectomy for Solitary Papillary Thyroid Microcarcinoma
To evaluate the clinical outcomes of image-guided thermal ablation versus thyroid lobectomy for the treatment of papillary thyroid microcarcinoma
- Trial name
- NCT06325787
- Testing
- thyroid lobectomy, image-guided thermal ablation
- Volunteers
- 1,021 people
- Sponsor
- Chinese PLA General Hospital
Type 2 Diabetes
Galvus (Vildagliptin) vs Placebo in Combination With Metformin and Insulin
The main objective is to show that the addition of Galvus versus placebo in patients with type 2 diabetes treated with metformin (at the maximum tolerated dose) and basal insulin properly titrated, allows a greater proportion of…
- Trial name
- NCT01757587
- Testing
- Vildagliptin
- Where
- France
- Volunteers
- 39 people
- Sponsor
- Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
Breast Cancer
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in…
- Trial name
- INAVO123 (NCT06790693)
- Testing
- Inavolisib, CDK4/6i, Letrozole
- Where
- 242 sites in United States, Argentina and 18 more
- Volunteers
- 450 people
- Sponsor
- Hoffmann-La Roche
Bariatric Surgery, Type 2 Diabetes
Fecal Microbiota Transfer to Improve Diabetes Control Post-bariatric Surgery
Obesity progresses worldwide with few effective treatments leading to a burst in Bariatric surgery (BS). France is the 3rd country in BS numbers yearly.
- Trial name
- DRIFTER (NCT06192693)
- Testing
- Capsulized fecal microbiota transfer containing the healthy feces + stool dilution solution
- Where
- France
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Recurrent Ovarian Cancer, Platinum Resistance
Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study
This trial was designed as a single-arm, open-label, prospective clinical trial to evaluate the efficacy (ORR) and safety (AE incidence) of CapsuleX in combination with cisplatin for platinum-resistant recurrent ovarian cancer…
- Trial name
- NCT07495384
- Testing
- CapsuleX
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Hospital of Jilin University
Blood Loss, Surgical
Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial
The main purpose of this study is to compare blood loss at the time of laparoscopic or robotically-assisted laparoscopic myomectomy when using different amounts of dilute vasopressin solution.
- Trial name
- NCT01393704
- Testing
- Vasopressin
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Brigham and Women's Hospital
Cerebral Stroke, Diabetes Mellitus
MRI Study of the Structural and Functional Rehabilitation in the Cerebral Infarction Patients With Diabetes
Diabetes mellitus (DM) plays an important role in the occurrence of the cerebral infarction (CI). Clinical studies have demonstrated that the CI patients with DM had a poor prognosis compared with those without DM.
- Trial name
- NCT02540733
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Zhejiang University
Growth Hormone Deficiency
Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21)
This study will recruit healthy controls (who have normal GH production and growth hormone levels) and patients identified as having GHD, who are deemed eligible for GH replacement therapy according to NICE guidelines.
- Trial name
- NCT02243852
- Testing
- Growth Hormone Replacement Therapy
- Where
- 2 sites in United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Liverpool
Growth Hormone Deficiency
Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under rhGH or LAGH With Stratification According to IGF-1 Levels
The METAB-BELGROW-LAGH study aims to prospectively evaluate the metabolic outcomes of Belgian children diagnosed with growth hormone deficiency (GHD) over a three-year period following the initiation of treatment with either…
- Trial name
- METAB-BELGROW (NCT07173036)
- Testing
- metabolic and auxological outcomes
- Volunteers
- 300 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Type 2 Diabetes, Overweight
The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients
The aim of this study is to evaluate the effect of glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on disordered eating behaviour in patients with overweight and type 2 diabetes.
- Conditions
- Type 2 Diabetes, Overweight, Disordered Eating Behaviors
- Trial name
- NCT06243536
- Testing
- Semaglutide, standard of care
- Where
- Croatia
- Volunteers
- 60 people
- Sponsor
- University Hospital Sestre Milosrdnice
Type 2 Diabetes
CGM Boosted by Artificial Intelligence for Better Glycaemic Control in T2 Diabetes
Title: CGM Boosted by Artificial Intelligence for better glycaemic control in T2 Diabetes : a real-life multicenter observational study in Belgium - MAGIC-T2D Background: In Belgium, since May 2023, reimbursement for continuous…
- Trial name
- MAGIC-T2D (NCT07064499)
- Where
- Belgium
- Volunteers
- 440 people
- Sponsor
- Erasme University Hospital
Osteoporosis, Diabetes Mellitus
A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers
Diabetes mellitus is a common disease with much impact on human's health and is related to osteoporosis. But the mechanism remains unclear.
- Trial name
- NCT02429232
- Testing
- Pioglitazone, Linagliptin
- Volunteers
- 160 people
- Sponsor
- National Taiwan University Hospital
Cystic Fibrosis, Prediabetes
Prevention of Cystic Fibrosis Diabetes
Acute systemic hyperglycemia causes oxidative stress and a pro-inflammatory response. The pro-inflammatory cytokines induced by hyperglycemia are toxic to islet insulin producing cells, and thus worsen glucose intolerance.
- Trial name
- Prevent (NCT00967798)
- Testing
- Sitagliptin
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Emory University
Type 2 Diabetes Mellitus, Mild Cognitive Impairment
Effects of Olfactory Training on the Brain Function in T2DM Patients With Mild Cognitive Impairment
This is a prospective, randomized, open label, parallel, 4-month study to explore and evaluate the therapeutic effects of olfactory training on the cognitive function, olfactory function, and odor-induced brain activation in T2DM…
- Trial name
- NCT06327633
- Testing
- Olfactory Training
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Obesity
STAGES Trial: Study of Adiposity, Growth and Endocrine Stages
The investigators propose to conduct a cross-sectional study of 60 participants who are 18-30 years of age to undergo research PET/CT.
- Trial name
- STAGES (NCT01460784)
- Where
- United States
- Volunteers
- 575 people, healthy volunteers welcome
- Sponsor
- University of Utah
Diabetes
Empowerment-based Complementary and Alternative Medicine (ECAM)
This phase study will use a randomized trial method to evaluate the performance of the ECAM educational app in the promotion of CAM health literacy and communication among patients with diabetes.
- Trial name
- CAM (NCT06317584)
- Testing
- Experimental: Empowerment Application for CAM Health Education, Written Paper for CAM Health Education
- Where
- Taiwan
- Volunteers
- 88 people
- Sponsor
- Chang Gung University of Science and Technology
Fallopian Tube Cancer, Ovarian Cancer
TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of TLK286 in treating patients who have advanced ovarian…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00022347
- Testing
- canfosfamide hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diabetic Kidney Disease, Proteinuria
An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
This study aims to observe changes in various indicators of renal function, such as proteinuria at different time points: short-term (Week 8), 6 months (Week 26), and a year (Week 52), in patients with DKD and hypertension, who…
- Conditions
- Diabetic Kidney Disease, Proteinuria, Hypertension,Essential
- Trial name
- FINALE (NCT05086549)
- Where
- South Korea
- Volunteers
- 360 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Ovarian Cancer, Endometrial Cancer
Sexual Health Integration in Treatment of Gynecological Oncology
The goal of this cross-section observational and questionary based study is to learn how geological cancer survivors perceive sexual health support given by health care professionals during diagnosis and treatment process.
- Conditions
- Ovarian Cancer, Endometrial Cancer, Cervical Cancers, Vaginal Cancers
- Trial name
- SHIFT-GO (NCT06958068)
- Where
- Poland
- Volunteers
- 324 people
- Sponsor
- Medical University of Silesia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.